Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
7,149,085
-
Share change
-
+69,102
-
Total reported value
-
$15,012,391
-
Put/Call ratio
-
4.7%
-
Price per share
-
$2.10
-
Number of holders
-
55
-
Value change
-
+$220,031
-
Number of buys
-
14
-
Number of sells
-
19
Institutional Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q1 2023
As of 31 Mar 2023,
GALECTIN THERAPEUTICS INC - COM NEW (GALT) was held by
55 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,149,085 shares.
The largest 10 holders included
VANGUARD GROUP INC, ADVISOR GROUP HOLDINGS, INC., BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, Geneos Wealth Management Inc., Atria Wealth Solutions, Inc., MORGAN STANLEY, Wealthspire Advisors, LLC, STATE STREET CORP, and Cambridge Investment Research Advisors, Inc..
This page lists
55
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.